(Q38191794)

30 August 2017

1 reference

title

Targeting tumour-supportive cellular machineries in anticancer drug development (English)

1 reference

30 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577400%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Ute Moll

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577400%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

1 March 2014

1 reference

Nature Reviews Drug Discovery

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577400%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577400%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

179-196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577400%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577400%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd4201

7 June 2020

exact match

0 references

cites work

Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders

1 reference

The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides

31 March 2020

1 reference

Targeted anti-mitotic therapies: can we improve on tubulin agents?

31 March 2020

1 reference

Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study

31 March 2020

1 reference

Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors

31 March 2020

1 reference

Paul Ehrlich's magic bullet concept: 100 years of progress.

31 March 2020

1 reference

Principles of cancer therapy: oncogene and non-oncogene addiction

31 March 2020

1 reference

MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms

31 March 2020

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

31 March 2020

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy

31 March 2020

1 reference

Defining the role of mTOR in cancer

31 March 2020

1 reference

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

31 March 2020

1 reference

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.

31 March 2020

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

31 March 2020

1 reference

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

31 March 2020

1 reference

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

31 March 2020

1 reference

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

31 March 2020

1 reference

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

31 March 2020

1 reference

TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

31 March 2020

1 reference

Mechanism of action and resistance to monoclonal antibody therapy

31 March 2020

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

31 March 2020

1 reference

Resistance to Trastuzumab in Breast Cancer.

31 March 2020

1 reference

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

31 March 2020

1 reference

Targeting the cancer kinome through polypharmacology

31 March 2020

1 reference

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

31 March 2020

1 reference

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

31 March 2020

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

31 March 2020

1 reference

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

31 March 2020

1 reference

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

31 March 2020

1 reference

31 March 2020

Cancer genome landscapes

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

HSP90 at the hub of protein homeostasis: emerging mechanistic insights

31 March 2020

1 reference

Proteotoxic stress of cancer: implication of the heat-shock response in oncogenesis

31 March 2020

1 reference

Targeting the dynamic HSP90 complex in cancer

31 March 2020

1 reference

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

31 March 2020

1 reference

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

31 March 2020

1 reference

Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells

31 March 2020

1 reference

Modulation of Akt kinase activity by binding to Hsp90

31 March 2020

1 reference

HSP90 and the chaperoning of cancer

31 March 2020

1 reference

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

31 March 2020

1 reference

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

31 March 2020

1 reference

Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy

31 March 2020

1 reference

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

31 March 2020

1 reference

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression

31 March 2020

1 reference

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

31 March 2020

1 reference

A small molecule inhibitor of inducible heat shock protein 70.

31 March 2020

1 reference

Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis

31 March 2020

1 reference

The proteasome: a suitable antineoplastic target

31 March 2020

1 reference

SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

31 March 2020

1 reference

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.

31 March 2020

1 reference

Cancer vulnerabilities unveiled by genomic loss

31 March 2020

1 reference

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

31 March 2020

1 reference

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

31 March 2020

1 reference

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

31 March 2020

1 reference

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

31 March 2020

1 reference

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

31 March 2020

1 reference

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

31 March 2020

1 reference

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

31 March 2020

1 reference

An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme

31 March 2020

1 reference

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

31 March 2020

1 reference

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance

31 March 2020

1 reference

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

31 March 2020

1 reference

31 March 2020

1 reference

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

31 March 2020

1 reference

Anticancer activities of histone deacetylase inhibitors

31 March 2020

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

31 March 2020

1 reference

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

31 March 2020

1 reference

Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes

31 March 2020

1 reference

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

31 March 2020

1 reference

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

31 March 2020

1 reference

Targeting MYC dependence in cancer by inhibiting BET bromodomains

31 March 2020

1 reference

Selective inhibition of BET bromodomains

31 March 2020

1 reference

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

31 March 2020

1 reference

Histone methyltransferases in cancer

31 March 2020

1 reference

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer

31 March 2020

1 reference

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

31 March 2020

1 reference

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

31 March 2020

1 reference

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

31 March 2020

1 reference

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

31 March 2020

1 reference

Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation

31 March 2020

1 reference

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

31 March 2020

1 reference

An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer

31 March 2020

1 reference

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach

31 March 2020

1 reference

High-throughput fluorescence microscopy for systems biology

31 March 2020

1 reference

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

31 March 2020

1 reference

Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity

31 March 2020

1 reference

Natural products in cancer chemotherapy: past, present and future

31 March 2020

1 reference

Interfacial inhibitors: targeting macromolecular complexes

31 March 2020

1 reference

From words to literature in structural proteomics

31 March 2020

1 reference

The spliceosome as a target of novel antitumour drugs

31 March 2020

1 reference

Towards patient-based cancer therapeutics

31 March 2020

1 reference

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

31 March 2020

1 reference

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

31 March 2020

1 reference

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

31 March 2020

1 reference

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

31 March 2020

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

31 March 2020

1 reference

A restricted cell population propagates glioblastoma growth after chemotherapy

31 March 2020

1 reference

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

31 March 2020

1 reference

Identification of selective inhibitors of cancer stem cells by high-throughput screening

31 March 2020

1 reference

Cancer stem cells: mirage or reality?

31 March 2020

1 reference

Systematic identification of genomic markers of drug sensitivity in cancer cells

31 March 2020

1 reference

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

31 March 2020

1 reference

Drug resistance and the solid tumor microenvironment

31 March 2020

1 reference

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

31 March 2020

1 reference

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

31 March 2020

1 reference

A paracrine requirement for hedgehog signalling in cancer

31 March 2020

1 reference

Tumor stroma as a target in cancer

31 March 2020

1 reference

Cancer biomarkers: selecting the right drug for the right patient

31 March 2020

1 reference

Cancer genes and the pathways they control

31 March 2020

1 reference

Genetic prognostic and predictive markers in colorectal cancer

31 March 2020

1 reference

Cell-cycle checkpoints and cancer

31 March 2020

1 reference

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

31 March 2020

1 reference

mTOR and cancer: insights into a complex relationship

31 March 2020

1 reference

Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action

31 March 2020

1 reference

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

31 March 2020

1 reference

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

31 March 2020

1 reference

Breast cancer after use of estrogen plus progestin in postmenopausal women

31 March 2020

1 reference

The first 30 years of p53: growing ever more complex

31 March 2020

1 reference

Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway

31 March 2020

1 reference

Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications

31 March 2020

1 reference

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

31 March 2020

1 reference

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

Origins and evolution of antibiotic resistance

31 March 2020

1 reference

More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance

31 March 2020

1 reference

Chromatin and the DNA damage response: the cancer connection.

31 March 2020

1 reference

Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.

31 March 2020

1 reference

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

31 March 2020

1 reference

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

31 March 2020

1 reference

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

31 March 2020

1 reference

Why does cytotoxic chemotherapy cure only some cancers?

31 March 2020

1 reference

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

31 March 2020

1 reference

PARP inhibition: PARP1 and beyond

31 March 2020

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

31 March 2020

1 reference

DNA repair dysregulation from cancer driver to therapeutic target

31 March 2020

1 reference

Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity

31 March 2020

1 reference

31 March 2020

1 reference

Microtubules as a target for anticancer drugs

31 March 2020

1 reference

Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

31 March 2020

1 reference

Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage

31 March 2020

1 reference

Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.

31 March 2020

1 reference

Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes

31 March 2020

1 reference

Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells.

31 March 2020

1 reference

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

31 March 2020

1 reference

Antibody therapeutics in cancer.

31 March 2020

1 reference

Antibody therapy of cancer

31 March 2020

1 reference

Trastuzumab emtansine for HER2-positive advanced breast cancer

31 March 2020

1 reference

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

31 March 2020

1 reference

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

31 March 2020

1 reference

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

31 March 2020

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study

31 March 2020

1 reference

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53

31 March 2020

1 reference

Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes

31 March 2020

1 reference

Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses

31 March 2020

1 reference

Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation

31 March 2020

1 reference

Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11.

31 March 2020

1 reference

The nucleolus: an emerging target for cancer therapy

31 March 2020

1 reference

Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.

31 March 2020

1 reference

Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation

31 March 2020

1 reference

New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action

31 March 2020

1 reference

Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

31 March 2020

1 reference

MicroRNA-cancer connection: the beginning of a new tale

31 March 2020

1 reference

Small molecule inhibition of RISC loading

31 March 2020

1 reference

Hsp90 regulates the function of argonaute 2 and its recruitment to stress granules and P-bodies

31 March 2020

1 reference

Dicer1 functions as a haploinsufficient tumor suppressor

31 March 2020

1 reference

MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways

31 March 2020

1 reference

Does the ribosome translate cancer?

31 March 2020

1 reference

Omacetaxine as an anticancer therapeutic: what is old is new again

31 March 2020

1 reference

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

31 March 2020

1 reference

The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation

31 March 2020

1 reference

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

31 March 2020

1 reference

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

31 March 2020

1 reference

Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer

31 March 2020

1 reference

BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

31 March 2020

1 reference

Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice

31 March 2020

1 reference

Identification of nuclear export inhibitors with potent anticancer activity in vivo

31 March 2020

1 reference

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

31 March 2020

1 reference

Understanding the Warburg effect: the metabolic requirements of cell proliferation

31 March 2020

1 reference

Pyruvate kinase M2 is a phosphotyrosine-binding protein

31 March 2020

1 reference

Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth

31 March 2020

1 reference

Targeting tumour metabolism

31 March 2020

1 reference

Targeting cancer metabolism

31 March 2020

1 reference

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

31 March 2020

1 reference

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

31 March 2020

1 reference

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

31 March 2020

1 reference

BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis

31 March 2020

1 reference

RETRACTED: Selective killing of cancer cells by a small molecule targeting the stress response to ROS

31 March 2020

1 reference

Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs

31 March 2020

1 reference

p53 opens the mitochondrial permeability transition pore to trigger necrosis

31 March 2020

1 reference

Mimicking the BH3 domain to kill cancer cells

31 March 2020

1 reference

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

31 March 2020

1 reference

Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

31 March 2020

1 reference

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

31 March 2020

1 reference

Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities

31 March 2020

1 reference

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

31 March 2020

1 reference

Potential therapeutic applications of autophagy

31 March 2020

1 reference

Autophagy as a target for anticancer therapy

31 March 2020

1 reference

Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications

31 March 2020

1 reference

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer

31 March 2020

1 reference

Cancer: Killing from the inside

31 March 2020

1 reference

Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase

31 March 2020

1 reference

Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.

31 March 2020

1 reference

New insights into the regulation and cellular functions of the ARP2/3 complex

31 March 2020

1 reference

HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein

31 March 2020

1 reference

A history of cancer chemotherapy

31 March 2020

1 reference

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

31 March 2020

1 reference

Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists

31 March 2020

1 reference

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

31 March 2020

1 reference

Camptothecin and taxol: discovery to clinic

31 March 2020

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

31 March 2020

1 reference

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

31 March 2020

1 reference

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

31 March 2020

1 reference

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

31 March 2020

1 reference

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

31 March 2020

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

31 March 2020

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

31 March 2020

1 reference

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

31 March 2020

1 reference

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

31 March 2020

1 reference

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

31 March 2020

1 reference

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

31 March 2020

1 reference

Improving treatment of HER2-positive cancers: opportunities and challenges

31 March 2020

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

31 March 2020

1 reference

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

31 March 2020

1 reference

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

31 March 2020

1 reference

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

31 March 2020

1 reference

Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists

31 March 2020

1 reference

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

31 March 2020

1 reference

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

31 March 2020

1 reference

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

31 March 2020

1 reference

31 March 2020

1 reference

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

31 March 2020

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

31 March 2020

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

31 March 2020

1 reference

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.

31 March 2020

1 reference

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

31 March 2020

1 reference

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib

31 March 2020

1 reference

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

31 March 2020

1 reference

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

31 March 2020

1 reference

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

31 March 2020

1 reference

Trastuzumab--mechanism of action and use in clinical practice

31 March 2020

1 reference

Brentuximab Vedotin (SGN-35).

31 March 2020

1 reference

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

31 March 2020

1 reference

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

31 March 2020

1 reference

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

31 March 2020

1 reference

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

31 March 2020

1 reference

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates

31 March 2020

1 reference

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

31 March 2020

1 reference

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

31 March 2020

1 reference

An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation

31 March 2020

1 reference

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

31 March 2020

1 reference

Oncogene-induced mitotic stress: p53 and pRb get mad too.

31 March 2020

1 reference

On the road to cancer: aneuploidy and the mitotic checkpoint

31 March 2020

1 reference

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

31 March 2020

1 reference

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

31 March 2020

1 reference

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

31 March 2020

1 reference

Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer

31 March 2020

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

31 March 2020

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

31 March 2020

1 reference

Panobinostat for the treatment of multiple myeloma

31 March 2020

1 reference

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension

31 March 2020

1 reference

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

31 March 2020

1 reference

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

31 March 2020

1 reference

Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging

31 March 2020

1 reference

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer

31 March 2020

1 reference

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

31 March 2020

1 reference

Valproic acid in the complex therapy of malignant tumors

31 March 2020

1 reference

Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors

31 March 2020

1 reference

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

31 March 2020

1 reference

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

31 March 2020

1 reference

The nucleolus under stress

31 March 2020

1 reference

RPA and ATR link transcriptional stress to p53

31 March 2020

1 reference

MDMX regulation of p53 response to ribosomal stress

31 March 2020

1 reference

Pharmacological targeting of endoplasmic reticulum stress signaling in cancer

31 March 2020

1 reference

Endoplasmic reticulum stress: cell life and death decisions.

31 March 2020

1 reference

Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase

31 March 2020

1 reference

Distinct autophagosomal-lysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest

31 March 2020

1 reference

Stimulation of arachidonic acid metabolism in rat peritoneal macrophages by thapsigargin, a non-(12-O-tetradecanoylphorbol-13-acetate) (TPA)-type tumor promoter

31 March 2020

1 reference

Cellular metabolic stress: considering how cells respond to nutrient excess.

31 March 2020

1 reference

Ageing, oxidative stress and cancer: paradigms in parallax

31 March 2020

1 reference

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

31 March 2020

1 reference

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

31 March 2020

1 reference

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer

31 March 2020

1 reference

12 December 2020

WASP and WAVE proteins: vital intrinsic regulators of cell motility and their role in cancer (review).

1 reference

12 December 2020

Spliceosome Structure and Function

1 reference

12 December 2020

Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells

1 reference

12 December 2020

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

1 reference

12 December 2020

Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A

1 reference

12 December 2020

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

12 December 2020

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

1 reference

12 December 2020

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

12 December 2020

ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect

1 reference

12 December 2020

THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.

1 reference

12 December 2020

The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides.

1 reference

12 December 2020

Protein oxidation in aging and age-related diseases

1 reference

12 December 2020